HILDEN, Germany & GERMANTOWN, Maryland–(BUSINESS WIRE)–QIAGEN NV (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its recently launched, more environmentally friendly QIAwave Nucleic Acid Extraction Kits have been awarded the prestigious ACT Environmental Impact Factor label. from My Green Lab, a non-profit organization dedicated to advancing sustainability in scientific research.
By assigning the ACT labels (Accountability, Consistency, and Transparency), My Green Lab found that the three QIAwave products had an improved environmental impact factor of 35% compared to QIAGEN’s standard kits, taking into account criteria such as reduced manufacturing impact, responsible management of chemicals, product content and packaging as well as disposal of packaging.
QIAGEN launched the QIAwave portfolio in January with the QIAwave RNA Mini Kit, QIAwave DNA Blood & Tissue Kit and QIAwave Plasmid Miniprep Kit. All are designed to use fewer components and produce less waste, and are the first kits of their kind to use both recycled plastics and space-saving chemical concentrates. They represent QIAGEN’s first wave of sustainability-focused product innovations and a major step in reducing the environmental impact of the company’s overall portfolio.
To date, My Green Lab has awarded the ACT seal to more than 4,000 products in the global life sciences industry, with QIAGEN’s products being the first nucleic acid extraction kits to receive this seal. approval of the respected independent arbitrator. Going forward, QIAGEN will work closely with the California-based organization to advance its Green Lab certification program, which aims to increase transparency around the environmental impact of research labs, and work towards certifying clean QIAGEN research and development laboratories.
“My Green Lab is focused on businesses to tackle the immense ecological challenges facing planet Earth head-on,” said Thomas Schweins, Senior Vice President and Business Line Leader of Life Sciences. QIAGEN life. “At QIAGEN, we take this challenge very seriously. Today’s recognition of our more eco-friendly kits is further proof of our commitment to sustainability and an important step in our campaign to significantly reduce the environmental impact of our entire product line.
QIAGEN aims to reduce plastic packaging waste by an additional 9% in 2022, following a 9.6% reduction achieved in 2021. The company’s Plastic Footprint Task Force, founded in 2018, manages initiatives such as replacing expanded polystyrene boxes for refrigerated shipments with recyclable alternatives. . Beyond reducing its plastic footprint, QIAGEN is committed to reducing carbon emissions in line with the goal of achieving Science Based Targets Net-Zero by 2050, and continuously monitors its environmental impact. world, its economic influence and its corporate citizenship. Sustainability agency ISS ESG awarded QIAGEN its highest Prime rating.
More information about QIAwave ACT labels can be found here.
More information on QIAGEN’s vision of a sustainable future can be found here.
QIAGEN NV, a Netherlands-based holding company, is the world’s leading provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sampling technologies isolate and process DNA, RNA and proteins from blood, tissues and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant and actionable insights. Automation solutions connect them in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers worldwide in molecular diagnostics (human health), applied testing (primarily forensics), pharmacy (pharmaceutical and biotechnology companies), and academia (research in life sciences). As of March 31, 2022, QIAGEN employed over 6,000 people at over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the US Securities Act of 1933, as amended, and Section 21E of the US Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein regarding QIAGEN’s products, collaboration markets, strategy or results of operations, including, without limitation, its adjusted net sales and results adjusted diluted expected, are forward-looking statements are based on current expectations and assumptions that involve a number of uncertainties and risks. These uncertainties and risks include, but are not limited to, risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability operating results and allocations between customer categories; business development of markets for our products to customers in academia, pharmaceuticals, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected technological changes; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, level and timing of customer funding, budgets and other factors); our ability to obtain regulatory approval for our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; QIAGEN’s ability to identify and develop new products and to differentiate and protect our products from competing products; market acceptance of new QIAGEN products and integration of acquired technologies and businesses. For more information, please refer to discussions in reports that QIAGEN has filed with or provided to the United States Securities and Exchange Commission (SEC).
Source: QIAGEN AG